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ered by interrogation of a dual-chamber pacemaker or
implantable cardioverter-defibrillator (ICD) is not estab-
lished. 
7: In one clinical trial (MOST), atrial high-rate episodes
lasting ≥5 minutes predicted a higher risk of death and non-
fatal stroke.  
8: In another trial (TRENDS), an AF burden >5.5 hours on
any of the preceding 30 days of monitoring was associated
with a 2.4%/year incidence of thromboembolism, twice the
risk in patients without AF.
9: In another trial (ASSERT), an atrial high-rate episode
lasting >6 minutes detected by a pacemaker or ICD was
associated with a 2.5-fold increase in the risk of stroke/sys-
temic embolism. 
10: There are no data to guide recommendations regarding
the optimal therapy of patients with very brief episodes of
AF by prolonged rhythm monitoring. 
Summary written by: Fred Morady, MD
Rivaroxaban Versus Warfarin in Nonvalvular Atrial
Fibrillation
Patel MR, Mahaffey KW, Garg J, et al., on behalf of the ROCKET
AF Investigators.
N Engl J Med 2011;Aug 10:[Epub ahead of print].
Study Question: Is rivaroxaban as effective as warfarin for pre-
venting strokes in patients with atrial fibrillation (AF)? 
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Arrhythmias
Prolonged Rhythm Monitoring for the Detection of
Occult Paroxysmal Atrial Fibrillation in Ischemic
Stroke of Unknown Cause
Seet RC, Friedman PA, Rabinstein AA.
Circulation 2011;124:477-486.
Perspective: The following are 10 points to remember about
occult paroxysmal atrial fibrillation (AF) in cryptogenic
stroke: 
1: In studies that have used predominantly automatic event
recorders or implantable loop recorders, ~6% of patients
who presented with a stroke or transient ischemic attack had
previously undiagnosed AF.
2: In studies restricted to patients with cryptogenic stroke,
the incidence of AF discovered by prolonged monitoring
was 14-27%.
3: Patients with AF more often have severe neurological
deficits compared to patients without AF.  
4: Among cryptogenic strokes limited to the anterior circula-
tion, the incidence of AF has been as high as 68%.
5: An embolic infarct pattern, age >65 years, and coronary
artery disease are associated with a higher probability of
finding AF by monitoring. 
6: The clinical significance of brief episodes of AF discov-   
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Warfarin usage ranged from 25-80% among the 20 practices
in the registry. 
Conclusions: Almost 50% of outpatients with AF who have a
CHADS2 score >1 and are at moderate to high risk of
stroke are not treated with warfarin.  
Perspective: This study confirms the results of prior studies that
have demonstrated widespread underutilization of warfarin in
AF patients with risk factor profiles that justify the use of war-
farin. It is likely that the inconveniences and risk of
hemorrhagic complications associated with warfarin are major
factors for underutilization. It is possible that dabigatran,
which is more convenient than warfarin, will improve the uti-
lization of oral anticoagulant therapy, but this remains to be
seen.
Summary written by: Fred Morady, MD
Cardiovascular Surgery
Intraoperative Direct Measurement of Left
Ventricular Outflow Tract Gradients to Guide
Surgical Myectomy for Hypertrophic
Cardiomyopathy
Ashikhmina EA, Schaff HV, Ommen SR, Dearani JA, Nishimura
RA, Abel MD.
J Thorac Cardiovasc Surg 2011;142:53-59.
Study Question: Is intraoperative direct measurement of left
ventricular outflow tract (LVOT) gradient important in the
management of patients with hypertrophic obstructive car-
diomyopathy (HOCM) undergoing transaortic septal
myectomy? 
Methods: This was a retrospective study assessing echocardio-
graphic and direct measurement of LVOT gradients in 198
patients (>18 years of age) with HOCM who underwent
transaortic septal myectomy. Evaluated baseline and pro-
voked LVOT gradients (Valsalva or inhaled amyl nitrate for
transesophageal echocardiography [TEE] and induced pre-
mature ventricular contraction or isoproterenol infusion
intraoperatively) were obtained by TEE and direct pressure
measurement in the left ventricle and aorta. 
Results: After induction of anesthesia and prior to myectomy,
LVOT gradient was significantly less severe by direct meas-
urement than by preoperative TEE in 60% of patients (p <
0.001), significantly more severe in 38% (p < 0.001), and the
same in only 2%. Provocation tests were performed preoper-
atively in 50% primarily in symptomatic patients with low
(<30 mm Hg) gradients. In all patients, the LVOT gradient
increased significantly with provocation. In 96% of patients,
the LVOT gradient significantly decreased after initial septal
myectomy by direct measurement and TEE (p < 0.001 for
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Methods: In this multicenter, double-blind trial, 14,264
patients (median age 73 years) with AF and a CHADS2
score ≥2 were randomly assigned to treatment with 20
mg/day of rivaroxaban (n = 7,131) or dose-adjusted warfarin
(n = 7,133). The target international normalized ratio (INR)
was 2-3. Median follow-up was 23.6 months. 
Results: The incidence of stroke and systemic embolism (pri-
mary endpoint) did not differ significantly between the
rivaroxaban (2.1%/year) and warfarin (2.4%/year) groups.
The rate of major and nonmajor bleeding also did not differ
significantly between the rivaroxaban (14.9%/year) and war-
farin (14.5%) groups. However, the rates of fatal bleeding
and intracranial hemorrhage were significantly lower in the
rivaroxaban (0.2 and 0.5%/year, respectively) than the war-
farin group (0.5% and 0.7%/year, respectively). 
Conclusions: Rivaroxaban is noninferior to warfarin for pre-
vention of stroke/embolism in patients with AF, and is
associated with a lower risk of fatal and intracranial hemor-
rhages. 
Perspective: As is the case with dabigatran, rivaroxaban is
administered in a fixed dosage and does not require titration
based on the INR. This is a major advantage over warfarin.
Several studies have demonstrated that warfarin is underuti-
lized in patients with AF who are at risk of stroke. The
availability of more convenient and probably safer oral antico-
agulants hopefully will promote improved utilization rates.
Summary written by: Fred Morady, MD
Practice-Level Variation in Warfarin Use Among
Outpatients With Atrial Fibrillation (From the NCDR
PINNACLE Program)
Chan PS, Maddox TM, Tang F, Spinler S, Spertus JA.
Am J Cardiol 2011;Jul 26:[Epub ahead of print].
Study Question: How often is warfarin underutilized in
patients with atrial fibrillation (AF) at moderate to high risk
of stroke? 
Methods: Data on 9,113 patients (mean age 76 years) with
AF and a CHADS2 score >1 were extracted from a national
prospective office-based quality improvement registry (PIN-
NACLE). The primary outcome was the rate of warfarin
therapy in these patients.  
Results: Fifty-five percent of the patients with a CHADS2
score >1 were treated with warfarin. There were no signifi-
cant differences in mean CHADS2 score, age, comorbid-
ities, or rate of prior stroke between the patients who did
and did not receive warfarin. There was no relationship
between the CHADS2 score and treatment with warfarin.
Among the patients not receiving warfarin, 51% were
treated with aspirin, 4% with a thienopyridine, and 10%
with aspirin plus a thienopyridine.
bleeding in 2 out of 171 outpatients (1.2%) versus no inpa-
tients within 14 days (95% UCL, 3.6%; p = 0.031). Up to
90 days, major bleeding was seen in 3 of 171 outpatients
(1.8%) versus no inpatients (95% UCL, 4.5%; p = 0.086). 
Conclusions: In selected low-risk patients with pulmonary
embolism, outpatient care can safely and effectively be used
in place of inpatient care. 
Perspective: This study should reassure providers that patients
with pulmonary embolism at low risk for mortality can
safely be treated in the outpatient setting, just as deep vein
thrombosis patients are treated. However, some caution is
warranted; the current study’s small size, and the lack of sur-
veillance for recurrent VTE, have led to very small numbers
of outcomes. Given that the anticipated rate of recurrent
VTE was 0.9%, a prespecified noninferiority margin of 4%
seems rather large.
Summary written by: James B. Froehlich, MD, MPH 
Mortality and Readmission of Patients With Heart
Failure, Atrial Fibrillation, or Coronary Artery
Disease Undergoing Noncardiac Surgery: An
Analysis of 38 047 Patients
van Diepen S, Bakal JA, McAlister FA, Ezekowitz JA.
Circulation 2011;124:289-296.
Study Question: What is the postoperative mortality rate of
patients with heart failure (HF), atrial fibrillation (AF), or
coronary artery disease (CAD) undergoing noncardiac sur-
gery?  
Methods: The authors created an inception cohort of patients
with incident HF, AF, or CAD, by linking the Alberta
Inpatient Discharge Abstracts Database, the Alberta Health
Care Insurance Registry, and the Ambulatory Care
Classification System for the province of Alberta, and then
evaluated outcomes during subsequent noncardiac surgery.
Subjects were divided into four groups based on cardiac
diagnosis: nonischemic HF (NIHF; n = 7,700), ischemic
HF (IHF; n = 12,249), CAD (n = 13,786), or AF (n =
4,312). Subsequent noncardiac surgery occurred between
April 1, 1999 and September 31, 2006. 
Results: Unadjusted 30-day mortality was 9.3% for NIHF,
9.2% for IHF, 2.9% for CAD, and 6.4% for AF (p < 0.0001
for each group vs. CAD). Similar results were seen looking
at 30-day postoperative mortality after minor surgical proce-
dures: 8.5% for NIHF, 8.1% for IHF, 2.3% for CAD, and
5.7% for AF (p < 0.0001 for each group versus CAD).
Multivariable adjustment suggested postoperative mortality
was higher for all three groups compared with CAD:
(NIHF odds ratio [OR], 2.92; 95% confidence interval
[CI], 2.44-3.48); (IHF OR, 1.98; 95% CI, 1.70-2.31); (AF
OR, 1.69; 95%, CI 1.34-2.14). 
both). Intraoperative TEE was technically inadequate in
assessing LVOT gradient in 38% of patients. 
Conclusions: Direct pressure measurements of LVOT gradi-
ents provide important information at baseline and
following septal myectomy to determine adequacy of repair
due to the significant number of patients demonstrating het-
erogeneous alterations in gradients under general anesthesia
compared to preoperative baseline TEE. 
Perspective: Due to the dynamic nature of LVOT obstruction
in patients with septal hypertrophy, it is imperative to have
an adequate assessment of the baseline LVOT gradient in
patients undergoing septal myectomy so there is an adequate
point for comparison under similar loading conditions. The
addition of provoked LVOT gradient pressure measure-
ments helps identify patients at risk for severe LVOT
obstruction with activity that may not be apparent at base-
line, and to ensure that it is adequately addressed at surgery
while the patient is under general anesthesia.
Summary written by: Jennifer C. Hirsch, MD
General Cardiology
Outpatient Versus Inpatient Treatment for Patients
With Acute Pulmonary Embolism: An International,
Open-Label, Randomised, Non-Inferiority Trial
Aujesky D, Roy PM, Verschuren F, et al.
Lancet 2011;378:41-48.
Study Question: What is the effectiveness, safety, and effi-
ciency of outpatient versus inpatient care for low-risk
patients with acute, symptomatic pulmonary embolism?
Methods: The authors reported the results of OTPE (Safety
Study of Outpatient Treatment for Pulmonary Embolism),
an open-label, randomized, noninferiority clinical trial of
adults over age 18 with acute, symptomatic pulmonary
embolism at low risk of death, randomly assigned to either
outpatient or inpatient treatment, conducted in 19 emer-
gency departments in Switzerland, France, Belgium, and the
United States. Outpatient and inpatient treatment included
subcutaneous low molecular weight heparin for at least 5
days, and oral anticoagulation for at least 90 days. The pri-
mary outcome was symptomatic recurrent venous
thromboembolism (VTE) within 90 days, as well as major
bleeding in 14 or 90 days, and mortality within 90 days. 
Results: Among 344 eligible subjects enrolled between
February 2007 and June 2010, recurrent VTE within 90
days was seen in 1 of 171 outpatients (0.6%) versus none in
168 inpatients (95% upper confidence limit [UCL], 2.7%; p
= 0.011). There was one death in each treatment group
within 90 days (95% UCL, 2.1%; p = 0.005), and major
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Conclusions: Although current perioperative risk prediction
models place greater emphasis on CAD than HF or AF,
patients with HF or AF had significantly higher risk of
postoperative mortality than patients with CAD, even after
minor surgical procedures.
Summary written by: James B. Froehlich, MD, MPH 
Adherence to Medication Under Mandatory and
Voluntary Mail Benefit Designs
Liberman JN, Hutchins DS, Shrank WH, Slezak J, Brennan TA
Am J Manag Care 2011;17:e260-e269
Study Question: Are there differences in medication adherence
rates under voluntary and mandatory pharmacy mail benefit
designs? 
Methods: A matched retrospective cohort study of adherence
rates in the first year of therapy was conducted by compar-
ing voluntary and mandatory mail cohorts. Inclusion criteria
were individuals who initiated statin, angiotensin-converting
enzyme (ACE) inhibitor, angiotensin-receptor blocker
(ARB), platelet aggregation inhibitor, metformin, glitazone,
or sulfonylurea therapy at a retail pharmacy between January
1 and March 31, 2009. Initiators in mandatory mail plans
were matched on therapeutic class, age, sex, prospective risk,
and cost of initial prescription with those in voluntary mail
plans. 
Results: Persistence rates were similar through the first 60
days of therapy. The mandatory mail cohort had a notable
drop in persistence by day 90 (63.3% vs. 56.3%, p < 0.001),
with a more pronounced drop among those without previ-
ous mail-service pharmacy use (50.5%). Median medication
possession ratio (49.2% vs. 57.4%) and optimal adherence
(33.6% vs. 36.1) were also lower. In the multivariable mod-
els, mandatory mail participants were less likely to achieve
optimal adherence overall (odds ratio [OR], 0.70; 95% con-
fidence interval [CI], 0.67-0.74) and in the metformin (OR,
0.55), sulfonylurea (OR, 0.72), ACE inhibitor (OR, 0.74),
ARB (OR, 0.69), and statin (OR, 0.69) classes. Participants
with no prior use of mail-service pharmacy had significantly
lower odds of achieving optimal adherence in all therapeutic
classes. 
Conclusions: Mandatory mail appears to cause some members
to discontinue therapy prematurely, particularly those with-
out previous mail service pharmacy experience. 
Perspective: The findings are not surprising and should have
been considered by the insurer and employer whose inten-
tions were to reduce costs and improve compliance with the
specific drugs studied. When members choose to discon-
tinue rather than switch pharmacy channels, the unintended 
consequence is a reduction in medication adherence and the
potential for increased medical expenses. 
Summary written by: Melvyn Rubenfire, MD 
Global Variation in the Relative Burden of Stroke
and Ischemic Heart Disease
Kim AS, Johnston SC.
Circulation 2011;124:314-323.
Study Question: What is the international variation in the bur-
den of stroke versus ischemic heart disease (IHD), and how
does this relate to the prevalence of risk factors and socio-
demographic factors? 
Methods: The authors analyzed data from World Health
Organization Global InfoBase, the WHO Global Burden of
Disease Program (GBD), and the World Bank. Estimates of
disease burden for IHD and stroke, as measured by disease-
related mortality and disability-adjusted life-year (DALY) loss
rates, were compiled from WHO GBD estimates for each
country, with age and sex standardized to the WHO global
standard. National prevalence of vascular risk factors was
compiled from the WHO Global InfoBase, and national
income data were derived from World Bank estimates. 
Results: Among 192 WHO member countries, stroke mortal-
ity exceeded IHD mortality in 74 countries (39%), and
stroke DALY rates exceeded IHD DALY rates in 62 coun-
tries (32%). Stroke mortality ranged from 12.7% higher to
27.2% lower than IHD mortality, and stroke DALY loss
ranged from 6.2% higher to 10.2% lower than for IHD.
Stroke burden of disease was disproportionately higher in
China, Africa, and South America, while IHD burden of
disease was higher in the Middle East, North America,
Australia, and much of Europe. Lower national income was
associated with higher mortality (p < 0.001) and higher bur-
den of disease (p = 0.001) from stroke. Diabetes and total
cholesterol were associated with greater IHD burden, even
after adjusting for national income.  
Conclusions: Substantial global variation in the relative burden
of stroke versus IHD exists, and the disproportionate burden
from stroke in many lower-income countries suggests that dis-
tinct interventions may be required.  
Perspective: This interesting study offers a unique perspective
on the relationship between sociodemographic factors, and the
presence of disproportionate risk for stroke disease versus
IHD. Risk factor disparities observed identify opportunities for
population health improvement, which will be very important
as the global epidemic of cardiovascular disease expands rapidly
into lower income countries.
Summary written by: James B. Froehlich, MD, MPH
1542 Eagle, Cannon
Scanning the Literature
JACC Vol. 57, No. 23, 2011
October 4, 2011:1539-46
Heart Failure/Transplant
Glycaemic Control and Incidence of Heart Failure in
20,985 Patients With Type 1 diabetes: An
Observational Study
Lind M, Bounias I, Olsson M, Gudbjörnsdottir S, Svensson AM,
Rosengren A.
Lancet 2011;378:140-146. 
Study Question: Is poor glycemic control associated with
increased risk for heart failure? 
Methods: Data from  patients over the age of 17 years with
type 1 diabetes who were registered in the Swedish national
diabetes registry between January 1998 and December 2003
were included in the study. Subjects with a prior history of
heart failure at baseline were excluded. Categories of glycated
hemoglobin (HbA1c) were primary exposure of interest, and
the primary outcome of heart failure was examined by these
categories.   
Results: A total of 20,985 patients were included (mean age
38.6 years, 45% women). Over a median follow-up of 9
years, 635 patients were admitted to the hospital with a pri-
mary or secondary diagnosis of heart failure, which was an
incidence of 3.38 events per 1,000 patients-years (95% confi-
dence interval [CI], 3.12-3.65). Incidence increased with
HbA1c, with a range of 1.42-5.20 per 1,000 patient-years
between patients in the lowest (<6.5%) and highest (≥10.5%)
categories of HbA1c. After adjustment for age, sex, duration
of diabetes, cardiovascular risk factors, and baseline or inter-
vening acute myocardial infarction and other comorbidities,
the risk for development of heart failure was 3.98 (95% CI,
2.23-7.14) for patients with an HbA1c of 10.5% or higher
compared to patients with an HbA1c of <6.5%. Risk of heart
failure increased with age and duration of diabetes. Other
modifiable factors associated with increased risk of heart fail-
ure were smoking, high systolic blood pressure, and raised
body mass index. 
Conclusions: A positive association between HbA1c and risk of
heart failure in fairly young patients with type 1 diabetes indi-
cates a potential for prevention of heart failure with improved
glycemic control. 
Perspective: This study, using data from a large-scale registry,
suggests an increased risk of heart failure among type 1 diabet-
ics with poor glucose control. It remains to be determined if
interventions that improve glucose control reduce risk for heart
failure.
Summary written by: Elizabeth A. Jackson, MD
Chronic Hypertension in Pregnancy
Seely EW, Ecker J.
N Engl J Med 2011;36:439-446.
Perspective: The following are 10 points to remember about
chronic hypertension in pregnancy: 
1: Chronic hypertension in pregnancy is defined as a systolic
blood pressure of at least 140 mm Hg or a diastolic blood
pressure of at least 90 mm Hg prior to pregnancy, or prior
to 20 weeks’ gestation if a patient first presents during preg-
nancy.
2: Women with chronic hypertension have an increased risk
of pregnancy-related complications, including pre-eclampsia,
placental abruption, fetal growth restriction, preterm birth,
and cesarean section.
3: Detailed prepregnancy counseling and evaluation should be
provided to women with chronic hypertension of childbearing
age. This should include education as to the maternal and
fetal risks of pregnancy, as well as medical therapies con-
traindicated during pregnancy. 
4: Methyldopa is the antihypertensive with the largest quan-
tity of data regarding fetal safety. Somnolence is a common
side effect, which may limit its use.
5: Labetalol is an effective antihypertensive, which is safe in
pregnancy. Beta-blockers have been associated with fewer
episodes of severe hypertension than methyldopa.
6: While treatment of chronic hypertension in pregnancy
reduces the risk of severe hypertension, it does not decrease
the risk of severe pre-eclampsia, placental abruption, or fetal
growth restriction, or improve fetal outcomes.
7: Guideline groups disagree on thresholds for initiation of
therapy and targets for therapy, although a reasonable goal is
to maintain blood pressures from 130/80 to 150/100 mm Hg.
8: Angiotensin-converting enzyme inhibitors are contraindi-
cated in pregnancy, as they have been associated with
oligohydramnios and neonatal anuria, growth abnormalities,
skull hypoplasia, and fetal death. Angiotensin-receptor block-
ers are also contraindicated.
9: Blood pressure can decrease during the second trimester of
pregnancy. Women on antihypertensives at the onset of preg-
nancy should be closely monitored, and their medications
decreased or discontinued as necessary. 
10: Most antihypertensives are compatible with breastfeeding.
Data are lacking for angiotensin-receptor blockers in breast-
feeding, so other agents should be considered.
Summary written by: Timothy B. Cotts, MD
JACC Vol. 57, No. 23, 2011
October 4, 2011:1539-46
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Improvements in Door to Balloon Time in the
United States, 2005-2010
Krumholz H, Herrin J, Miller L, et al.
Circulation 2011;Aug 22:[Epub ahead of print].
Study Question: What has been the change in door-to-balloon
time (D2BT) in the United States over the last 5 years? 
Methods: The authors assessed the change in D2BT based on
primary percutaneous coronary intervention (PCI) data sub-
mitted by all hospitals in the United States to Centers for
Medicare & Medicaid Services from January 2005 to
September 2010. 
Results: There has been a dramatic improvement in D2BT
nationally, with the median D2BT declining from 96 min-
utes to 64 minutes. The proportion of patients undergoing
primary PCI within 90 minutes increased from 44% to 94%,
and those undergoing PCI within 75 minutes increased
from 27% to 70%. 
Conclusions: Considerable progress has been achieved nation-
ally in providing rapid primary PCI of patients with
ST-segment elevation myocardial infarction. 
Perspective: This study provides an overview of the dramatic
reduction in D2BT that has been achieved over the last 5
years nationally as a direct result of the efforts of many peo-
ple working at the national, institutional, and local level.
The improvement in D2BT must be followed by efforts to
reduce symptom-to-balloon time so that timely reperfusion
can be achieved in the majority of patients.
Summary written by: Hitinder S. Gurm, MBBS
Physician Specialty and Carotid Stenting Among
Elderly Medicare Beneficiaries in the United States
Nallamothu BK, Lu M, Rogers MA, Gurm HS, Birkmeyer JD.
Arch Intern Med 2011;Aug 8:[Epub ahead of print].
Study Question: What is the current specialty composition of
operators performing carotid stenting in the United States
and the extent to which specialty of operator explains varia-
tion in its utilization and outcomes across different health
care markets?
Methods: The investigators performed an observational analy-
sis of fee-for-service Medicare beneficiaries 65 years or older
undergoing carotid stenting between 2005 and 2007 in 306
hospital referral regions (HRRs). They first determined how
frequently carotid stenting was performed by different spe-
cialists within each HRR and then used multivariable
regression models to compare population-based utilization
rates and 30-day outcomes for this procedure across HRRs
based on the proportion performed by cardiologists, sur-
geons, radiologists, or a mix of specialists.
Results: In 272 HRRs where at least 15 procedures were per-
formed during the study period, the investigators identified
28,700 carotid stenting procedures performed by 2,588 oper-
ators. While cardiologists made up approximately one-third
of these operators, they were responsible for 14,919 (52.0%)
procedures. Significant differences were noted in the charac-
teristics of patients treated by cardiologists compared with
other specialties, including higher rates of invasive cardiac
procedures and lower rates of acute stroke or transient
ischemic attacks in the 180 days prior to carotid stenting.
Population-based utilization rates were significantly higher
in HRRs where cardiologists performed most procedures
relative to HRRs where most were done by other specialists
(p < 0.001). In contrast, risk-standardized outcomes did not
differ across HRRs based on physician specialty. 
Conclusions: HRRs where cardiologists perform most proce-
dures have higher population-based utilization rates with
similar outcomes. 
Perspective: This study suggests that cardiologists in the
United States play an important role in carotid stenting, and
HRRs where cardiologists performed most carotid stenting
had higher population-based utilization rates than other
HRRs with similar outcomes. Additional studies are needed
to better understand the specific nature of this relationship
and whether multidisciplinary decision making by teams of
specialists could optimize the use and appropriateness of this
innovative technology.
Summary written by: Debabrata Mukherjee, MD
Prevention/Vascular
Cigarette Smoking as a Risk Factor for Coronary
Heart Disease in Women Compared With Men: A
Systematic Review and Meta-Analysis of
Prospective Cohort Studies
Huxley RR, Woodward M.
Lancet 2011;Aug 11:[Epub ahead of print].
Study Question: What is the effect of smoking on coronary heart
disease (CHD) in women compared with men after account-
ing for sex differences in other major risk factors? 
Methods: The investigators undertook a systematic review
and meta-analysis of prospective cohort studies published
between January 1, 1966, and December 31, 2010, from four
online databases. They selected cohort studies that were
stratified by sex with measures of relative risk (RR), and
associated variability, for CHD and current smoking com-
pared with not smoking. The investigators pooled data with
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a random-effects model with inverse variance weighting,
and estimated RR ratios (RRRs) between men and women. 
Results: The investigators reviewed 8,005 abstracts and
included 26 articles with data for 3,912,809 individuals and
67,075 CHD events from 86 prospective trials. In 75
cohorts (2.4 million participants) that adjusted for cardio-
vascular risk factors other than CHD, the pooled adjusted
female-to-male RRR of smoking compared with not smok-
ing for CHD was 1.25 (95% confidence interval, 1.12-1.39;
p < 0.0001). The RRR increased by 2% for every additional
year of study follow-up (p = 0.03). In pooled data from 53
studies, there was no evidence of a sex difference in the RR
between participants who had previously smoked compared
with those who never had (RRR, 0.96; 95% CI, 0.86-1.08;
p = 0.53). 
Conclusions: Whether mechanisms underlying the sex differ-
ence in risk of CHD are biological or related to differences in
smoking behavior between men and women is unclear. 
Perspective: This review suggests that, compared with non-
smokers, women who smoke may have a 25% greater RR of
CHD than do male smokers, independent of other cardiovas-
cular risk factors. Given the present trends in female smoking,
inclusion of a female perspective in smoking cessation pro-
grams and policies is going to be crucial from a public health
perspective.
Summary written by: Debabrata Mukherjee, MD
Minimum Amount of Physical Activity for Reduced
Mortality and Extended Life Expectancy:
A Prospective Cohort Study
Wen CP, Wai JP, Tsai MK, et al.
Lancet 2011;Aug 16:[Epub ahead of print]. 
Study Question: What are the health benefits of a range of
volumes of physical activity in a Taiwanese population? 
Methods: In this prospective cohort study, 416,175 individu-
als (199,265 men and 216,910 women) participated in a
standard medical screening program in Taiwan between
1996 and 2008, with an average follow-up of 8.05 years. On
the basis of the amount of weekly exercise indicated in a
self-administered questionnaire, participants were placed
into one of five categories of exercise volumes: inactive, or
low, medium, high, or very high activity. The investigators
calculated hazard ratios (HRs) for mortality risks for every
group compared with the inactive group, and calculated life
expectancy for every group. 
Results: Compared with individuals in the inactive group,
those in the low-volume activity group, who exercised for
an average of 92 minutes per week (95% confidence interval
[CI], 71-112) or 15 minutes a day, had a 14% reduced risk
of all-cause mortality (0.86, 0.81-0.91), and had a 3-year
longer life expectancy. Every additional 15 minutes of daily
exercise beyond the minimum amount of 15 minutes a day
further reduced all-cause mortality by 4% (95% CI, 2.5-7.0)
and all-cancer mortality by 1% (0.3-4.5). These benefits
were applicable to all age groups and both sexes, and to
those with cardiovascular disease risks. Individuals who
were inactive had a 17% (HR, 1.17; 95% CI, 1.10-1.24)
increased risk of mortality compared with individuals in the
low-volume group.  
Conclusions: Fifteen minutes a day or 90 minutes a week of
moderate-intensity exercise might be of benefit, even for indi-
viduals at risk of cardiovascular disease. 
Perspective: This study suggests that ~15 minutes of moder-
ate-intensity exercise had significant health benefits. In the
study population, if inactive individuals engaged in low-vol-
ume daily exercise, one in six all-cause deaths could be
postponed. Use of this minimum amount of exercise can
reduce mortality from heart disease, diabetes, and cancer.
This low volume of physical activity could play a major part
in the global war against cardiovascular diseases, diabetes,
and cancer, improving overall health of the population
while reducing medical costs and health disparities.
Summary written by: Debabrata Mukherjee, MD
Dose Response Between Physical Activity and Risk
of Coronary Heart Disease: A Meta-Analysis
Sattelmair J, Pertman J, Ding EL, Kohl HW 3rd, Haskell W, Lee
IM.
Circulation 2011;124:789-795.
Study Question: What amount of physical activity is required
to lower risk of coronary heart disease (CHD) when assess-
ing the dose response? 
Methods: An aggregate data meta-analysis was conducted of
epidemiological studies investigating physical activity and pri-
mary prevention of CHD. After reviewing 3,194 abstracts,
the authors included 33 prospective cohort studies published
in English since 1995. A random-effects generalized least
squares spline model was used for trend estimation to derive
pooled dose-response estimates. 
Results: An aggregate data meta-analysis was conducted of
epidemiological studies investigating physical activity and pri-
mary prevention of CHD. After reviewing 3,194 abstracts,
the authors included 33 prospective cohort studies published
in English since 1995. A random-effects generalized least
squares spline model was used for trend estimation to derive
pooled dose-response estimates. 
Conclusions: The findings provide quantitative data supporting
US physical activity guidelines, which stipulate that “some
physical activity is better than none” and “additional benefits
occur with more physical activity.” 
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Perspective: This excellent meta-analysis speaks for itself. The
only weakness is the inability to have a uniform definition
for CHD between studies.
Summary written by: Melvyn Rubenfire, MD
Accuracy of Stated Energy Contents of Restaurant
Foods
Urban LE, McCrory MA, Dallal GE, et al.
JAMA 2011;306:287-293.
Study Question: Are reported calorie counts for restaurant food
accurate?
Methods: A total of 269 food items and 242 unique foods were
measured for dietary energy using a validated bomb calorime-
try technique. Foods were chosen from 42 restaurants. Both
foods and restaurants were randomly selected from quick-
serve and sit-down restaurants in Massachusetts, Arkansas,
and Indiana between January and June 2010. The primary
outcome was the difference between restaurant-stated and
laboratory measured energy contents, which were corrected
for standard metabolizable energy conversion factors. 
Results: Overall, the stated energy contents were not signifi-
cantly different from the measured energy contents (p =
0.52). However, of the 269 food items, 50 (19%) contained
measured energy contents of at least 100 kcal/portion more
than the stated energy contents. Of the 10% of foods with
the highest excess energy in the initial sampling, 13 of 17
were available for a second sampling. In the first analysis,
these foods contained average measured energy contents of
289 kcal/portion (95% confidence interval [CI], 186-392
kcal/portion) more than the stated energy contents; in the
second analysis, these foods contained average measured
energy contents of 258 kcal/portion (95% CI, 154-361
kcal/portion) more than the stated energy contents. In addi-
tion, foods with lower stated energy contents contained
higher measured energy content than stated, while foods
with higher stated energy contents contained lower meas-
ured energy contents. Side dishes from sit-down restaurants
contained higher measured energy contents than stated
compared with the entrees they accompanied, and were sig-
nificantly more variable relative to measured energy content. 
Conclusions: Stated energy contents of restaurant foods were
accurate overall. However, there was substantial inaccuracy for
some individual foods, with understated energy contents for
those with lower energy contents. 
Perspective: This study provides valuable information on food
consumed outside of the home. Since many Americans fre-
quently eat meals outside the home, information on
variability of caloric content reported versus actual calories
has important implications for those attempting to lose
weight.
Summary written by: Elizabeth A. Jackson, MD
n-3 Polyunsaturated Fatty Acids in the Prevention
of Atrial Fibrillation Recurrences After Electrical
Cardioversion
Nodari S, Triggiani M, Campia U, et al.
Circulation 2011;Aug 15:[Epub ahead of print].
Study Question: Do n-3 polyunsaturated fatty acids (PUFAs)
prevent recurrences of atrial fibrillation (AF) after car-
dioversion? 
Methods: One hundred ninety-nine patients (mean age 70
years, 90% with structural heart disease) with persistent AF
were treated with amiodarone, 200 mg/day, and the maxi-
mally-tolerated dose of an angiotensin-converting enzyme
inhibitor (ACEI) or angiotensin-receptor blocker (ARB).
One month before cardioversion, the patients were randomly
assigned to treatment with 1 g twice daily of PUFAs (n =
100) or a placebo (n = 99). Treatment was continued for 1
year. 
Results: Sinus rhythm was present at 1 year of follow-up
significantly more often in the PUFA (62%) than the
placebo group (36%). After adjustment for confounding
variables such as left atrial size, the only variable independ-
ently associated with sinus rhythm at 1 year was treatment
with PUFAs.
Conclusions: When used in conjunction with amiodarone and
an ACEI or ARB, PUFAs prevent recurrent AF after car-
dioversion. 
Perspective: These results seemingly are at odds with the
results of a randomized study (Kowey PR, et al., JAMA
2010;304:2363-72), in which PUFAs were found to not pre-
vent recurrences of paroxysmal or persistent AF. However,
those patients did not have structural heart disease and were
not treated with amiodarone. It is possible that PUFAs exert
an antiarrhythmic effect only in the presence of structural
remodeling and in conjunction with amiodarone.
Summary written by: Fred Morady, MD
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